Related Experiment Video

Updated: May 8, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Low amount of salinomycin greatly increases Akt activation, but reduces activated p70S6K levels

Ju-Hwa Kim1, Ae-Ran Choi, Yong Kee Kim

  • 1Research Institute, National Cancer Center, Ilsan-gu, Goyang-si, Gyeonggi-do 410-769, Korea. jua@ncc.re.kr

International Journal of Molecular Sciences
|August 27, 2013
PubMed

Insights

Salinomycin (Sal) cancer treatment resistance involves Akt activation. This study reveals Akt signaling promotes cancer cell survival and Sal resistance, identifying a novel sensitization mechanism.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Salinomycin (Sal) is an ionophore with potential anticancer properties.
  • Cancer cells can develop resistance to chemotherapeutic agents, limiting treatment efficacy.
  • Understanding resistance mechanisms is crucial for improving cancer therapy.

Purpose of the Study:

  • To investigate the signaling pathways involved in cancer cell resistance to Sal.
  • To identify novel Sal-sensitization mechanisms in cancer cells.
  • To explore the role of the PI3K/Akt/mTOR pathway in Sal resistance.

Main Methods:

  • Analysis of signal proteins (Akt, Jnk, p38, Jak, Erk1/2) in Sal-treated cancer cell lines.
  • Assessment of PI3K/Akt/mTOR pathway components (PI3K, PDK1, GSK3β, p70S6K, mTOR, PTEN).
  • Evaluation of Akt activation and C-PARP production in response to varying Sal doses and co-treatment with Akt inhibitors.

Main Results:

  • Sal sensitization correlated with reduced p70S6K activation.
  • Akt was significantly activated by Sal treatment, dependent on the PI3K pathway.
  • Akt activation and C-PARP production increased proportionally with Sal dose, indicating enhanced cell survival and resistance.

Conclusions:

  • Akt activation promotes cancer cell resistance to Sal.
  • Increased Akt signaling in surviving cells suggests a mechanism for Sal resistance.
  • Targeting Akt may represent a strategy to sensitize cancer cells to Sal treatment.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...